Axcella Announces Initiation of EMMPOWER^℠ Phase II Clinical Trial of AXA1665

Axcella, announced that it has activated initial clinical sites and patient screening for its global Phase II clinical trial of AXA1665, the company’s multi-targeted oral product candidate for the reduction in risk of recurrent overt hepatic encephalopathy.